Sponsored by the University of Medicine & Dentistry of New Jersey (UMDNJ), and the New Jersey Medical School Global Tuberculosis Institute

Original Release Date: June 2002 • Activity Update: April 1, 2008 • Expiration Date: March 31, 2010
Nursing credit for this activity will be provided through March 31, 2010

This activity is supported by educational grants from Monarch Pharmaceuticals for the first edition release and JHP Pharmaceuticals for the release of the second edition.

Target Audience

This activity is designed for internists, pediatricians, pulmonologists, infectious disease specialists, public health and preventive medicine specialists, nurses, and other health personnel interested or involved in tuberculosis diagnosis, treatment and prevention of tuberculosis and latent tuberculosis infection.

Learning Objectives

Upon the completion of this activity, participants should be able to:

bullet Describe the role of tuberculin testing in low prevalence countries
bullet Review how tuberculins are developed, manufactured and validated
bullet Recognize minor disparities in commercially available tuberculins and the necessity of serial testing with the same antigen
bullet Explain the protocol for administering and reading tuberculin skin tests
bullet Correctly interpret repeated tuberculin skin tests
bullet Examine the role of tuberculin reactions produced by cross reactions with non-tuberculous mycobacteria
bullet Differentiate the use of interferon-γ release assays when compared to tuberculin skin testing
bullet Discuss the role of the nurse in the diagnosis of latent TB infection

Method of Instruction

Participants should read the learning objectives and the activity in its entirety. After reviewing the material, complete the post-test consisting of a series of multiple-choice questions.

Upon completing this activity as designed, click the CE Credit button to go to our online Test, Evaluation, and Certificate System where you will register to take the Continuing Education Test and complete the Evaluation.

You must obtain at least a 70% passing grade to receive your Continuing Education Certificate. You will be given unlimited opportunities to succeed. Once you have obtained a 70% passing grade you will then complete the Evaluation and you will be presented with your Continuing Education Certificate.

Estimated time to complete this activity as designed is 3.5 hours.

Accreditation

Physicians: UMDNJ–Center for Continuing and Outreach Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing education for physicians.

UMDNJ–Center for Continuing and Outreach Education designates this educational activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses: UMDNJ–Center for Continuing and Outreach Education is an approved provider of continuing nursing education by NJSNA, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity is awarded 3.5 contact hours (60 minute CH).

Provider approved by the California Board of Registered Nursing, Provider Number CEP 13780.

This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by Lee B. Reichman, MD, MPH and Rajita Bhavaraju, MPH; and pilot-tested for time required for participation by Anju Budhwani, MD, Henry S. Fraimow, MD, DJ McCabe, RN, MSN, and Lillian Pirog, RN, PNP.

Disclosure

In accordance with the disclosure policies of UMDNJ and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this education activity are required to disclose to the activity participants: 1) the existence of any financial interest or other relationships with propriety entities producing health care goods and services, with the exemption of non-profit or government organizations and non-health care related companies, within the past  12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

The faculty and editors listed below have declared that they have no significant financial relationships or affiliations to disclosure:

John-Manuel Andriote, MS
Kitty Lambregts, MD, PhD, MPH
Rajita Bhavaraju, MPH
Alfred Lardizabal, MD
George Comstock, MD, DrPH
Richard Menzies, MD, MSc
Karen Galanowsky, RN, MPH
Sheldon L. Morris, PhD
Elsa Villarino, MD, MPH

Lee B. Reichman, MD, MPH is a consultant for and shareholder of Cellestis, Inc.

The pilot-testers listed below have declared that they have no significant financial relationships or affiliations to disclosure:

Anju Budhwani, MD
DJ McCabe, RN, MSN
Henry S. Fraimow, MD
Lillian Pirog, RN, PNP

Disclaimer

The views expressed in this publication are those of the faculty. It should not be inferred or assumed that they are expressing the views of Monarch and JHP Pharmaceuticals, any other manufacturer of pharmaceuticals, or UMDNJ.

The drug selection and dosage information provided in this publication are believed to be accurate. However, the reader is urged to consult the full prescribing information on any drug mentioned in this publication for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

Copyright © 2008 UMDNJ-Center for Continuing and Outreach Education. All rights reserved including translation into other languages. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from UMDNJ-Center for Continuing and Outreach Education.

To review UMDNJ’s privacy policy: http://ccoe.umdnj.edu/general/privacypolicy.html.

Please direct continuing education related questions to UMDNJ at 800-227-4852 or email ccoe@umdnj.edu.

System Requirements

This activity should be viewed at a resolution of 1024 x 768 or higher using Microsoft Internet Explorer 6 or later.


>>Next